Plasmid gene delivery to human keratinocytes through a fibrin-mediated transfection system.
We have developed a matrix-mediated transfection system to deliver plasmids to human keratinocytes. The matrix is a soluble, self-hardening fibrin matrix (Tissucol), Baxter) that has been used clinically. Recently it has been shown that full thickness burn wounds can be successfully treated with a keratinocyte fibrin glue suspension. Further, it has been demonstrated that hEGF transfected cells accelerate wound healing. In this study, we inoculated the matrix with the hEGF expression plasmid and resuspended the matrix with either cultured or noncultured human keratinocytes. We obtained successful transfection rates of these cells (up to a 100-fold increase compared to controls containing no EGF expression plasmid) in vitro. After transplantation to full thickness wounds on athymic mice we were able to show a 180-fold increase in EGF concentration compared to controls, which persisted over the entire 7-day monitored period, decreasing from 180 to 20 pg/mL at day seven. This unique approach indicates the possible utility to combine a matrix for cell transplantation with a transfection system to release therapeutic proteins in vitro and in vivo.
Andree
C
C
Department of Plastic Surgery, University Hospital Freiburg, Freiburg, Germany. Andree@ch11.ukl.uni-freiburg.de
Voigt
M
M
Wenger
A
A
Erichsen
T
T
Bittner
K
K
Schaefer
D
D
Walgenbach
K J
KJ
Borges
J
J
Horch
R E
RE
Eriksson
E
E
Stark
G B
GB
D000818:Animals; D017690:Cell Transplantation / Q000379:methods; D004815:Epidermal Growth Factor / Q000235:genetics; D005337:Fibrin; D006801:Humans; D015603:Keratinocytes / Q000502:physiology*; D051379:Mice; D008819:Mice, Nude; D010957:Plasmids / Q000235:genetics*; D023822:Tissue Engineering; D014162:Transfection / Q000379:methods*; D014945:Wound Healing
D004815:Epidermal Growth Factor; D005337:Fibrin